Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp demonstrates a strong potential for revenue growth, with expectations of increasing revenue in the high teens to low twenties as the trend shifts from in-person to digital interactions in the pharma/provider landscape. The company's current operational capabilities support a substantial revenue run-rate of approximately $150 million, indicating built-in operating leverage that bodes well for future performance. With gross margins reaching 74.8% and record EBITDA of $12 million, significantly surpassing estimates, OptimizeRx is positioned to rebound robustly as it capitalizes on its integrated offerings and the anticipated success of its RWE-AI product cycle.

Bears say

OptimizeRx's stock outlook is negatively impacted by a significant reduction in its 2026 revenue guidance, which has been lowered to $109 million-$114 million from previous expectations of $118 million-$124 million, reflecting ongoing headwinds primarily from large pharma clients facing pricing initiatives. The company anticipates weak revenue and earnings results through the first half of 2026, forecasting declines around 10% year-over-year in the first two quarters, amidst escalating pressure stemming from the pharmaceutical industry's struggle with recent pricing policies. Additionally, notable declines in net revenue retention and a decrease in visibility regarding contracted revenues contribute to a more challenging growth environment, with EBITDA margins projected to decrease due to this revenue deceleration.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.